Krystal Biotech, Inc. KRYS
308.81 USD +2.31 (+0.75%)
At closeNov 11, 2026, 4:26 PM EST
308.81 0.00 0.00%
After hours · Nov 11, 4:26 PM ET
303.59 Day range 310.93
198.02 52-week range 382.54
- YTD
- +25.26%
- 1 year
- +52.12%
News
defenseworld.net Revolution Medicines (NASDAQ:RVMD) vs. Krystal Biotech (NASDAQ:KRYS) Head-To-Head Survey Krystal Biotech (NASDAQ: KRYS - Get Free Report) and Revolution Medicines (NASDAQ: RVMD - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two…
defenseworld.net Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Now Rated “Moderate Buy” by Wall Street Analysts Krystal Biotech, Inc. (NASDAQ: KRYS - Get Free Report) has been given an average rating of "Moderate Buy" by the fourteen analysts that are currently covering the firm, MarketBeat Ratings reports.…
benzinga.com Citigroup Maintains Buy on Krystal Biotech, Lowers Price Target to $412 Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and lowers the price target from $416 to $412.
benzinga.com TD Cowen Maintains Buy on Krystal Biotech, Lowers Price Target to $380 TD Cowen analyst Ritu Baral maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and lowers the price target from $403 to $380.
benzinga.com RBC Capital Maintains Outperform on Krystal Biotech, Lowers Price Target to $375 RBC Capital analyst Lisa Walter maintains Krystal Biotech (NASDAQ:KRYS) with a Outperform and lowers the price target from $400 to $375.
benzinga.com Krystal Biotech Analyst Says Stock Weakness 'Overblown' Krystal Biotech Inc. (NASDAQ:KRYS) stock is trading lower on Monday after the company provided a third-quarter update.
benzinga.com Krystal Biotech Analyst Says Stock Weakness 'Overblown' Krystal Biotech beats Q3 earnings, but trial delays send shares lower. Analysts call the market drop overblown and highlight a potential buying opportunity.
seekingalpha.com Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call Transcript Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call Transcript
zacks.com Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $2.05 per share, beating the Zacks Consensus Estimate of $1.84 per share. This compares to earnings of $2.66 per share a year ago.
schaeffersresearch.com Nasdaq Rallies as Tech Stocks Recover From Friday's Selloff Stocks are higher midday as tech stocks bounce back as peace-talk hopes grew while fanning oil prices
marketbeat.com Krystal Biotech Q3 Earnings Call Highlights Krystal Biotech NASDAQ: KRYS reported third-quarter 2026 revenue growth driven by continued adoption of its VYJUVEK treatment in the United States and international markets, while also outlining…
benzinga.com Krystal Biotech Q3 2026 Earnings Call Transcript Krystal Biotech (NASDAQ:KRYS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com Krystal Biotech Q3 EPS $2.05 Beats $1.77 Estimate, Sales $127.341M Beat $126.079M Estimate Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $2.05 per share which beat the analyst consensus estimate of $1.77 by 15.82 percent. This is a 22.93 percent decrease over earnings of…
globenewswire.com Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results $127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch VYJUVEK pricing negotiations in Germany and Italy completed KB113 clinical data demonstrate regression in more than 80% of…
benzinga.com Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test Apple headlines Monday’s reports, with investors looking for continued iPhone momentum and evidence that its artificial-intelligence push can support the company’s next leg of growth. Marriott…
zacks.com Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
benzinga.com Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 31.65% on an annualized basis producing an average annual return of 42.52%. Currently, Krystal Biotech has a market…
globenewswire.com Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026 PITTSBURGH, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2026 financial results on Monday, November 2,…
zacks.com KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome Krystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.
benzinga.com HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $361 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a Buy and maintains $361 price target.
benzinga.com Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial Krystal Biotech reports clinical updates for KB113, showing over an 80% reduction in basal cell carcinoma lesions in Gorlin syndrome.- benzinga.com Krystal Biotech Highlights Broad Antitumor Responses With KB113 In Gorlin Syndrome Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113Substantial regression was observed in lesions not directly injected with KB113,…
globenewswire.com Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 Substantial regression was observed in lesions not directly injected with KB113,…
defenseworld.net 2,490 Shares in Krystal Biotech, Inc. $KRYS Purchased by Terra Nova Asset Management LLC Terra Nova Asset Management LLC purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ: KRYS) during the third quarter, according to the company in its most recent 13F filing with the…
seekingalpha.com Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value Krystal Biotech is rated a 'Buy' due to strong Vyjuvek sales, robust profitability, and a promising pipeline. Vyjuvek, approved for DEB, is on track for blockbuster status in my view with $119.2m Q2…
fool.com Breakfast News: Week in Review Yields hit a 24-year high as SpaceX borrows $40 billion for Nvidia chips, and more…
fool.com Breakfast News: 10 Moves to Fatten Your Nest Egg Plan your retirement in 10 steps, SpaceX wants to buy $40B of Nvidia chips, and more…
benzinga.com $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 33.19% on an annualized basis producing an average annual return of 45.63%. Currently, Krystal Biotech has a market…
benzinga.com Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.16% on an annualized basis producing an average annual return of 44.36%. Currently, Krystal Biotech has a market…
benzinga.com Goldman Sachs Reinstates Buy on Krystal Biotech, Announces $441 Price Target Goldman Sachs analyst Andrea Newkirk reinstates Krystal Biotech (NASDAQ:KRYS) with a Buy and announces $441 price target.
benzinga.com B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $400 B of A Securities analyst Alec Stranahan maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $392 to $400.
defenseworld.net Corient Private Wealth LP Grows Stock Position in Krystal Biotech, Inc. $KRYS Corient Private Wealth LP boosted its position in Krystal Biotech, Inc. (NASDAQ: KRYS) by 767.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities…
defenseworld.net Hsbc Holdings PLC Invests $3.65 Million in Krystal Biotech, Inc. $KRYS Hsbc Holdings PLC purchased a new stake in Krystal Biotech, Inc. (NASDAQ: KRYS) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The…- benzinga.com Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.48% on an annualized basis producing an average annual return of 43.76%. Currently, Krystal Biotech has a market…
zacks.com Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally? KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.
globenewswire.com Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference PITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference…- benzinga.com Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.97% on an annualized basis producing an average annual return of 44.08%. Currently, Krystal Biotech has a market…
- benzinga.com RBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400 RBC Capital analyst Lisa Walter initiates coverage on Krystal Biotech (NASDAQ:KRYS) with a Outperform rating and announces Price Target of $400.
benzinga.com If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 31.0% on an annualized basis producing an average annual return of 42.63%. Currently, Krystal Biotech has a market…- benzinga.com Citigroup Maintains Buy on Krystal Biotech, Raises Price Target to $386 Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $378 to $386.
- benzinga.com Krystal Biotech Q2 EPS $1.79 Beats $1.66 Estimate, Sales $119.222M Miss $121.061M Estimate Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.79 per share which beat the analyst consensus estimate of $1.66 by 7.83 percent. This is a 38.76 percent increase over earnings of…
- benzinga.com Krystal Biotech To Replace Taylor Morrison Home In The S&P MidCap 400, And Tutor Perini To Replace Krystal Biotech In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On Friday, July 24 https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20260720-1484359/1484359_tmhc-avns-46.pdf
benzinga.com Earnings Scheduled For May 4, 2026 - benzinga.com Earnings Scheduled For February 17, 2026
benzinga.com Earnings Scheduled For November 3, 2025 
benzinga.com 6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.
benzinga.com Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results - benzinga.com Earnings Scheduled For August 4, 2025
- benzinga.com Earnings Scheduled For May 6, 2025
- benzinga.com Earnings Scheduled For February 19, 2025